FLT3 anticorps (APC)

N° du produit ABIN2658478

Détail du produit anti-FLT3 anticorps (APC)

Antigène: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp FLT3 est conjugé à/à la APC

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.

Clone: BV10A4H2

Isotype: IgG1 kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur FLT3

Antigène: FLT3 (Fms-Related tyrosine Kinase 3 (FLT3))

Autre désignation: CD135 (FLT3 Produits)

Synonymes: anticorps FLT3, anticorps B230315G04, anticorps CD135, anticorps Flk-2, anticorps Flk2, anticorps Flt-3, anticorps Ly72, anticorps wmfl, anticorps FLK-2, anticorps FLK2, anticorps STK1, anticorps fms related tyrosine kinase 3, anticorps FMS-like tyrosine kinase 3, anticorps fms-related tyrosine kinase 3, anticorps FLT3, anticorps Flt3

Sujet: CD135 is a 130-160 kD type III tyrosine kinase receptor expressed on CD34+ hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. CD135 is also expressed on malignant hematopoietic cells including AML, ALL and CML-BC. CD135, also known as FMS-like tyrosine kinase-3, FLT3, STK-1, and Flk-2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. The intracytoplasmic domain of CD135 is modified by phosphorylation and has been shown to interact with Grb2, SOCS1, VAV1, and Shc.

Pathways: Signalisation RTK